Literature DB >> 23419299

Courier: a better font for reading with age-related macular degeneration.

Luminita Tarita-Nistor1, Dianne Lam, Michael H Brent, Martin J Steinbach, Esther G González.   

Abstract

OBJECTIVE: This study examines the reading performance of patients with age-related macular degeneration (AMD) using 4 readily available fonts.
DESIGN: Experimental study. PARTICIPANTS: Twenty-four patients with bilateral AMD participated.
METHODS: Reading performance (reading acuity, critical print size, and maximum reading speed) was measured for all patients, using 4 versions of the MNRead charts. These charts were printed in the following fonts: Times New Roman (serif, proportionally spaced), Arial (sans serif, proportionally spaced), Courier (serif, mono spaced), and Andale Mono (sans serif, mono spaced).
RESULTS: Reading acuity was significantly better on the Courier chart (0.58±0.21 logMAR) and significantly worse on the Arial chart (0.69±0.20 logMAR) than on any of the other charts (P<0.05). A larger proportion of patients were able to read≥1 sentences on the Courier chart than on any of the other charts. Reading speed dropped below the limit for fluent reading first with the Arial chart. There was no difference in maximum reading speed with the 4 fonts, and differences in critical print size failed to reach significance (P = 0.052).
CONCLUSIONS: Font has an effect on the reading performance of patients with AMD at print sizes close to their reading acuity. Courier was the most advantageous and Arial the worst font for reading smaller print. This is contrary to the advice given by agencies for the blind.
Copyright © 2013 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23419299     DOI: 10.1016/j.jcjo.2012.09.017

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  10 in total

1.  General practice: font and centre.

Authors:  Simon Morgan
Journal:  Br J Gen Pract       Date:  2015-09       Impact factor: 5.386

2.  Impact of simulated micro-scotomas on reading performance in central and peripheral retina.

Authors:  Arun Kumar Krishnan; Hope M Queener; Scott B Stevenson; Julia S Benoit; Harold E Bedell
Journal:  Exp Eye Res       Date:  2018-06-28       Impact factor: 3.467

3.  Fonts Designed for Macular Degeneration: Impact on Reading.

Authors:  Ying-Zi Xiong; Ethan A Lorsung; John Stephen Mansfield; Charles Bigelow; Gordon E Legge
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-08-01       Impact factor: 4.799

4.  Reading Digital with Low Vision.

Authors:  Gordon E Legge
Journal:  Visible Lang       Date:  2016-08

5.  Bolder print does not increase reading speed in people with central vision loss.

Authors:  Susana T L Chung; Jean-Baptiste Bernard
Journal:  Vision Res       Date:  2018-11-06       Impact factor: 1.886

Review 6.  Reading in the presence of macular disease: a mini-review.

Authors:  Susana T L Chung
Journal:  Ophthalmic Physiol Opt       Date:  2020-01-11       Impact factor: 3.117

7.  Training to improve temporal processing of letters benefits reading speed for people with central vision loss.

Authors:  Susana T L Chung
Journal:  J Vis       Date:  2021-01-04       Impact factor: 2.240

8.  A comparison of reading, in people with simulated and actual central vision loss, with static text, horizontally scrolling text, and rapid serial visual presentation.

Authors:  Farah Akthar; Hannah Harvey; Ahalya Subramanian; Simon Liversedge; Robin Walker
Journal:  J Vis       Date:  2021-11-01       Impact factor: 2.240

9.  Online Survey of Digital Reading by Adults with Low Vision.

Authors:  Yueh-Hsun Wu; Christina Granquist; Rachel Gage; Michael D Crossland; Gordon E Legge
Journal:  Optom Vis Sci       Date:  2020-04       Impact factor: 2.106

10.  Enhanced text spacing improves reading performance in individuals with macular disease.

Authors:  Sally Blackmore-Wright; Mark A Georgeson; Stephen J Anderson
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.